Abstract
Purpose :
The iStent trabecular micro-bypass stent (iStent) is performed in patients with mild to moderate glaucoma undergoing cataract extraction. While the benefit of this combined procedure (phaco-iStent) in lowering intraocular pressure (IOP) as well as reducing the burden of ocular anti-hypertensive medications has been well documented, the impact of patient ethnicity on these outcomes has yet to be addressed.
The purpose of this retrospective cohort study is to compare surgical outcomes in African American and Caucasian glaucoma patients who underwent phaco-iStent.
Methods :
74 Caucasian and 27 African American Phaco-iStent cases performed at Edward Hines Jr. Veterans Affairs Hospital were examined. Pre-operative IOP and number of ocular anti-hypertensive medications were recorded for every case. This was repeated for post-operative month 1, 3, 6, and 12. Regression analysis was performed.
Results :
Pre-operative IOP was 16.8 ± 4.2 and 17.0 ± 5.1 in Caucasian and African American patients respectively. Post-operative month 1, 3, 6, and 12 IOP for Caucasian patients were 14.7 ± 3.2, 13.4 ± 2.8, 13.7 ± 2.8, and 13.8 ± 2.3. African American post-operative month 1, 3, 6, and 12 IOP were 15.4 ± 4.2, 13.5 ±2.8, 14.1 ±3.5, and 15.0 ± 4.1.
Pre-operative number of ocular anti-hypertensive medications were 2.1 ± 1.2 and 2.7 ± 1.2 in Caucasian and African American patients respectively. Post-operative month 1, 3, 6, and 12 number of ocular anti-hypertensive medications for Caucasian patients were 1.5 ± 1.3, 1.6 ± 1.3, and 1.7 ± 1.2. African American post-operative month 1, 3, 6, and 12 medications were 2.3 ± 1.5, 2.7 ± 1.5, 2.3 ± 1.5, and 2.7 ± 1.8.
Regression analysis showed no statistically significant difference in surgical outcomes between African American and Caucasian Glaucoma patients.
Conclusions :
No statistically significant difference was found between IOP reduction or reduction in ocular anti-hypertensive medications between African American and Caucasian glaucoma patients after phaco-iStent. Further research on the impact of patient ethnicity and MIGS is warranted.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.